Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 116 clinical trials
Featured trial
A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

  • 08 Nov, 2020
  • 1 location
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

boost of radiotherapy to the residual tumour will be delivered immediately after the end of the cRT. Stratum 3 This stratum is designed as a phase II trial to evaluate the benefit of

  • 21 Oct, 2021
  • 64 locations
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

  • 23 Apr, 2022
  • 1 location
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole. This study aims to evaluate whether …

  • 26 Jul, 2022
  • 17 locations
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

breast cancer
adjuvant therapy
invasive breast cancer
  • 09 Jul, 2022
  • 6 locations
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer (IPLA-OVCA)

eradicating tumours but, paradoxically, also for proliferation and invasion of residual cancer cells. It increases the shedding of malignant cells into the blood and lymphatic circulations, inhibits their

cytoreductive surgery
fallopian tube
ovarian cancer stage
surgery for ovarian cancer
  • 11 Jul, 2022
  • 1 location
A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLC

incomplete surgical resection and residual tumor. Since the 21st century, with the rapid development of surgery and new science and technology, the diagnosis and treatment of liver diseases have been closely

  • 25 Mar, 2022
  • 1 location
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

  • 27 Jan, 2021
  • 1 location
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.

pet-ct scan
progesterone receptor
core needle biopsy
  • 20 Jun, 2022
  • 43 locations
Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers

The Radium Hospital Oslo University Hospital Estimated date of first patient enrolled: 3rd quarter 2021 Anticipated recruitment period: 4 years Estimated date of last patient completed: 4th quarter 2025 Locally advanced pelvic cancer that requires total pelvic exenteration Expected study-specific follow-up period per patient: 5 years according to standard follow-up …

  • 23 Mar, 2022